Analyst Research Report Snapshot

Title:

INNATE PHARMA – AN INNATELY COMPELLING STORY

Price:

$10.00

Provider:

Edison Investment Research

Date:

09 Jan 2014

Pages:

9

Type:

AcrobatPDF

Companies referenced:

IPH.PA

Available for Immediate Download
Summary:

Innate Pharma's lirilumab is one of the most promising oncology products being developed. The Phase I trials run by its partner Bristol-Myers Squibb in combination with the high-profile antibodies, ipilimumab and nivolumab, are advancing as expected. Preclinical data presented at December's ASH meeting also indicated that lirilumab might be able to enhance the activity of many other oncology antibodies. Innate Pharma has just raised €20.3m, which will help it develop its pipeline. We raise our valuation to €259m.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.